2024 Sponsors & Exhibitors

At Median, we transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for sponsors worldwide. To learn more, visit https://mediantechnologies.com/

Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V- domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS 102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit: www.senseibio.com

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology. For more information, visit: https://scailyte.com/

Scorpion Therapeutics is pioneering Precision Oncology 2.0 to deliver transformational therapies for larger populations of cancer patients. By combining our scientific expertise with advanced technologies, we exceed the performance of traditional discovery methods and develop molecules that are either best-in-class against validated oncogene targets or first-in-class for previously undruggable targets. For more information, please visit: www.scorpiontx.com

TD2 provides innovative services for improved and accelerated development of medicines for cancer. Our team has deep experience and understanding in drug development. Preclinical development, combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. To learn more, visit www.td2inc.com

Detai Bioscience, Inc. established in 2013, is a CRO vendor focusing on antibody discovery and functional protein research field. DetaiBio is aiming to provide high quality and economic service to speed up life science for our client in different fields, such as antibody drug discovery, in-vitro diagnosis and academic research. To learn more, please visit www.detaibio.us

MERIT is an oncology endpoint expert providing image collection, centralized reading, and data management services for clinical trials since 2012. We have supported hundreds of trials across 58 countries. MERIT partners with CROs as well as pharma and biotech companies to deliver reliable endpoint services in global clinical trials. To learn more, please visit meritcro.com

Canopy Biosciences, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary technology ChipCytometry™ is a quantitative multiplex immunofluorescence imaging method for the spatial analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services™ with our CLIA-certified laboratory, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at canopybiosciences.com

Elephas is leading the way to change how clinicians treat cancer patients. The Elephas platform uses human Live Tumor Fragments (hLTF)TM and combines the latest advances in cancer biology, multimodal microscopy, and artificial intelligence to predict immunotherapy response. The Elephas platform empowers clinical decision making and accelerates drug development. To learn more, please visit www.elephas.com

Headquartered in Needham, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, as well as their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ. Invicro is part of REALM IDx, Inc., a healthcare company that is pioneering the field of integrated diagnostics (IDx), a new frontier of advanced clinical science that brings together laboratory medicine, radiology, pathology, and sophisticated artificial intelligence to derive actionable insights that can lead to better medical solutions for patient care. Learn more at www.invicro.com

Radiomics is an imaging research organization which focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Founded in 2016, Radiomics has its HQ in LégiaPark in Liege, Belgium and a North American office in Toronto, Canada. For further information, visit www.radiomics.bio

Inimmune is a private clinical stage company dedicated to developing immuno-therapeutics. It is focused on advancing its Toll Like Receptor ligand portfolio as vaccine adjuvants, and immuno-therapeutics to be used alone or in combination to treat cancer, allergy, autoimmune disorders and infectious diseases. The company, through its chemistry, formulation and immunology expertise participates in a number of NIH-sponsored research collaborations with leading U.S. based universities developing vaccines to treat a variety of conditions including infectious diseases and opioid addiction. To learn more please visit: https://inimmune.com/